474 related articles for article (PubMed ID: 38023241)
21. Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma and
Dong Y; Xu C; Su G; Li Y; Yan B; Liu Y; Yin T; Mou S; Mei H
Front Immunol; 2023; 14():1122570. PubMed ID: 37275895
[TBL] [Abstract][Full Text] [Related]
22. Construction of an immune-related gene signature for overall survival prediction and immune infiltration in gastric cancer.
Ma XT; Liu X; Ou K; Yang L
World J Gastrointest Oncol; 2024 Mar; 16(3):919-932. PubMed ID: 38577455
[TBL] [Abstract][Full Text] [Related]
23. Identifying an immunogenic cell death-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma.
Li X; Zhang D; Guo P; Ma S; Gao S; Li S; Yuan Y
Aging (Albany NY); 2024 Apr; 16(7):6290-6313. PubMed ID: 38575204
[TBL] [Abstract][Full Text] [Related]
24. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
Front Immunol; 2022; 13():916800. PubMed ID: 35860239
[TBL] [Abstract][Full Text] [Related]
25. A Novel Prognostic Model Based on Ferroptosis-Related Gene Signature for Bladder Cancer.
Yang L; Li C; Qin Y; Zhang G; Zhao B; Wang Z; Huang Y; Yang Y
Front Oncol; 2021; 11():686044. PubMed ID: 34422642
[TBL] [Abstract][Full Text] [Related]
26. Identification and Validation of an Individualized Prognostic Signature of Bladder Cancer Based on Seven Immune Related Genes.
Qiu H; Hu X; He C; Yu B; Li Y; Li J
Front Genet; 2020; 11():12. PubMed ID: 32117435
[TBL] [Abstract][Full Text] [Related]
27. A risk model based on pyroptosis subtypes predicts tumor immune microenvironment and guides chemotherapy and immunotherapy in bladder cancer.
Wu T; Li S; Yu C; Wu Y; Long H
Sci Rep; 2022 Dec; 12(1):21467. PubMed ID: 36509838
[TBL] [Abstract][Full Text] [Related]
28. Characterization of an Autophagy-Immune Related Genes Score Signature and Prognostic Model and its Correlation with Immune Response for Bladder Cancer.
Yu J; Mao W; Sun S; Hu Q; Wang C; Xu Z; Liu R; Chen S; Xu B; Chen M
Cancer Manag Res; 2022; 14():67-88. PubMed ID: 35023971
[TBL] [Abstract][Full Text] [Related]
29. Construction and validation of a bladder cancer risk model based on autophagy-related genes.
Shen C; Yan Y; Yang S; Wang Z; Wu Z; Li Z; Zhang Z; Lin Y; Li P; Hu H
Funct Integr Genomics; 2023 Jan; 23(1):46. PubMed ID: 36689018
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma.
Wang L; Wang L; He P
Front Genet; 2022; 13():1064432. PubMed ID: 36568383
[No Abstract] [Full Text] [Related]
31. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
32. Identification of prognostic gene signature associated with microenvironment of lung adenocarcinoma.
Yue C; Ma H; Zhou Y
PeerJ; 2019; 7():e8128. PubMed ID: 31803536
[TBL] [Abstract][Full Text] [Related]
33. The G protein-coupled receptor-related gene signatures for predicting prognosis and immunotherapy response in bladder urothelial carcinoma.
Wan Z; Wang Y; Li C; Zheng D
Open Life Sci; 2023; 18(1):20220682. PubMed ID: 37588995
[TBL] [Abstract][Full Text] [Related]
34. Construction and validation of a gene signature related to bladder urothelial carcinoma based on immune gene analysis.
Xing P; Jiang Z; Liu Y
BMC Cancer; 2022 Aug; 22(1):926. PubMed ID: 36030212
[TBL] [Abstract][Full Text] [Related]
35. Construction of cancer- associated fibroblasts related risk signature based on single-cell RNA-seq and bulk RNA-seq data in bladder urothelial carcinoma.
Liu Y; Jian J; Zhang Y; Wang L; Liu X; Chen Z
Front Oncol; 2023; 13():1170893. PubMed ID: 37124542
[TBL] [Abstract][Full Text] [Related]
36. Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer.
Chen X; Qin Z; Zhu X; Wang L; Li C; Wang H
Sci Rep; 2023 Dec; 13(1):21816. PubMed ID: 38071230
[TBL] [Abstract][Full Text] [Related]
37. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
Shen C; Chai W; Han J; Zhang Z; Liu X; Yang S; Wang Y; Wang D; Wan F; Fan Z; Hu H
Front Immunol; 2023; 14():1213947. PubMed ID: 37965307
[TBL] [Abstract][Full Text] [Related]
38. A Novel Ferroptosis-Related Gene Model for Overall Survival Predictions of Bladder Urothelial Carcinoma Patients.
Zhang M; Zhang X; Yu M; Zhang W; Zhang D; Zeng S; Wang X; Hu X
Front Oncol; 2021; 11():698856. PubMed ID: 34386423
[TBL] [Abstract][Full Text] [Related]
39. Identification and Development of Inflammatory Response-Related Genes Signature Associated With Prognosis Evaluation and Immune Status of Bladder Cancer.
Zheng H; Luo W; Li Y; Peng G; Zhou D; Tang D; Cheng J; Wu S
Front Cell Dev Biol; 2022; 10():837849. PubMed ID: 35309900
[No Abstract] [Full Text] [Related]
40. Comprehensive analysis of cuproptosis-related lncRNAs signature to predict prognosis in bladder urothelial carcinoma.
Zhu S; Li H; Fan Y; Tang C
BMC Urol; 2023 Jul; 23(1):124. PubMed ID: 37479989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
